Home | PHARMAC
Home | PHARMAC
  • Website
  • Application Tracker
  • Schedule
  • About PHARMAC
    • About PHARMAC
    • Your guide to PHARMAC
    • Our history
    • Our people
    • Expert advice
    • PHARMAC's performance
    • Operating policies and procedures
    • Year in review 2018
    • Strategies
  • Medicines
    • Medicines
    • How medicines are funded
    • Medicines information
    • My medicine or medical device has changed
    • Your health
    • Hospital pharmaceuticals
    • New medicines – from development to funding
    • Equity
  • Hospital devices
    • Hospital devices
    • What's happening in each category?
    • PHARMAC's approach to hospital devices
    • Device Advice
    • PHARMAC medical devices forums 2017
  • News
  • Te Whaioranga
    • Te Whaioranga
    • Te Whaioranga 2013 - 2023: Māori Responsiveness Strategy
    • Whānau Ora
    • He Rongoā Pai, He Oranga Whānau
    • One Heart Many Lives
    • Scholarships
    • Hauora Arotahi - Māori health areas of focus
    • Māori Responsiveness Team
  • Pacific
    • Pacific
    • Pacific responsiveness strategy
    • Pacific action plan
  • Tools & resources
    • Tools & resources
    • Pharmaceutical Schedule
    • Annual Procurement Plan
    • Forms
    • Research
    • Print and PDF resources
    • Glossary
    • PHARMAC labelling preferences for prescription pharmaceuticals
  • Information for…
  1. About PHARMAC /
  2. PHARMAC's performance /
  3. Quarterly reports /
  4. 2017/2018 Q3

See more about this section

About PHARMAC

  • Your guide to PHARMAC
  • Our history
  • Our people
  • Expert advice
  • PHARMAC's performance
    • Relationship agreements
    • Quarterly reports
      • 2018/2019 Q1
      • 2017/2018 Q3
      • 2017/2018 Q2
      • 2017/2018 Q1
      • 2016/2017 Q3
      • 2016/2017 Q2
      • 2016/2017 Q1
      • 2015/2016 Q3
      • 2015/2016 Q2
      • 2015/2016 Q1
      • 2014/2015 Q3
      • 2014/2015 Q2
      • 2014/2015 Q1
    • Accountability information
    • Stakeholder surveys
  • Operating policies and procedures
  • Year in review 2018
  • Strategies

About PHARMAC

  • Your guide to PHARMAC
  • Our history
  • Our people
  • Expert advice
  • PHARMAC's performance
    • Relationship agreements
    • Quarterly reports
      • 2018/2019 Q1
      • 2017/2018 Q3
      • 2017/2018 Q2
      • 2017/2018 Q1
      • 2016/2017 Q3
      • 2016/2017 Q2
      • 2016/2017 Q1
      • 2015/2016 Q3
      • 2015/2016 Q2
      • 2015/2016 Q1
      • 2014/2015 Q3
      • 2014/2015 Q2
      • 2014/2015 Q1
    • Accountability information
    • Stakeholder surveys
  • Operating policies and procedures
  • Year in review 2018
  • Strategies

PHARMAC performance 2017/18 Q3

Performance data to 31 March 2018

Output Class 1: Decision-making

Measure: Savings are generated to meet the cost of future volume growth and allow for new investments.

Status: On track. Savings are generated to meet the cost of future volume growth and allow for new investments.

Measure: Savings are made from hospital medicines to enable new investments.

Status: On track. Five year cumulative savings to the health system of all decisions since 2013/14 is $227.39 million in hospital medicines.

Five year cumulative savings to the health system of all decisions made in 2017/18 is $42.37 million in hospital medicines.

Measure: The total value and number of hospital medical devices under contract increases.

Status: On track. The Pharmaceutical Schedule increased by around 2,000 line items in the third quarter. Contract value by 1 May 2018 was approximately $170 to $180 million per annum (an increase of $10 to $15 million in the third quarter).

Output Class 2: Influencing medicines use

Measure: DHB hospital engagement with PHARMAC compared with previous year.

Status: On track. All DHBs continue to receive new contracts for medical device products which provide potential for further savings opportunities. 

Measure: Survey of attendants at a PHARMAC Seminar show a positive professional change in optimal use behaviour as a result of attendance.

Status: On track. Seven seminars from 2017/18 have been surveyed.  An average of 82.5 per cent of survey respondents have made changes as a result of attending PHARMAC seminars.

Measure: Medicines use community health programmes are delivered to a range of health and community workers.

Status: On track. Community-based delivery of programmes has occured in over half of all our Whanau Ora Collective (WOC) partner areas. The number of WOC partners increased from 13 to 14 partners during the third quarter.

Measure: Low medicine stock situations are identified and managed so that there are no clinically meaningful consequences to patients.

Status: On track. PHARMAC has worked with suppliers to identify, monitor and manage all low medicine stock reports.

Output Class 3: Providing policy advice and support

Measure: PHARMAC staff participate in and contribute to wider sector forums.

Status: On track. PHARMAC continues to actively instigate and participate in various engagements across the health sector. 

Measure: All rebates are collected and distributed to DHBs in accordance with PHARMAC policy.

Status: On track. All PHARMAC fund use is in accordance with PHARMAC policy.

Last updated: 3 May 2018

About this site

  • Sitemap
  • Copyright
  • Disclaimer
  • Privacy statement
  • This site is operated by PHARMAC, the Pharmaceutical Management Agency.

Contact

  • Contact us
  • Twitter - PHARMACnz
  • Facebook - PHARMACnz
  • YouTube - PHARMACgovtnz
  • LinkedIn - Pharmaceutical Management Agency (PHARMAC)
  • Careers
  • Newsfeed

Back to top

New Zealand Government